Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Brown Fat Activity and White Fat Accumulation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vicente Gilsanz, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier:
NCT01517581
First received: January 20, 2012
Last updated: January 24, 2012
Last verified: January 2012

January 20, 2012
January 24, 2012
October 2008
September 2011   (final data collection date for primary outcome measure)
  • Change from Baseline in Subcutaneous Adipose Tissue Volume at Follow-up [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
  • Change from Baseline in Visceral Adipose Tissue Volume at Follow-up [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
  • Change from Baseline in Presence of Brown Adipose Tissue [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
  • Change from Baseline in Abdominal Musculature Volume [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01517581 on ClinicalTrials.gov Archive Site
Change from Baseline in Anthropometric Measures at Follow-up [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
Age, height, weight and BMI
Same as current
Not Provided
Not Provided
 
Brown Fat Activity and White Fat Accumulation
Study on the Association Between Brown Adipose Tissue Activation and White Adipose Tissue Accumulation in Successfully Treated Pediatric Malignancy

White and brown adipocytes differ in their expression of hormones, cytokines, and inflammatory factors, and they modulate different biological functions. While white adipose tissue (WAT) serves as the primary site of energy storage, brown adipose tissue (BAT) instead metabolizes fat to produce heat and regulate body temperature. BAT is likely present in all humans, but the low prevalence of BAT depiction in adults and elderly subjects has hindered longitudinal assessments of the relation between BAT activity and WAT. Under typical imaging conditions, BAT is detected more frequently in children and teenagers than in adults with malignancy. Since most children with cancer have significantly shorter treatment courses and greater survival rates compared to adult patients, the investigators have the ability to examine the relation of repeated measures of body composition and BAT by selecting pediatric patients. In this study, the investigators will longitudinally examine whether BAT activity is related to changes in weight and the amounts of SAT, VAT, and abdominal muscle in children successfully treated for pediatric cancer.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Pediatric patients with a history of malignancy such that they are required to undergo PET/CT exams.

  • Hodgkins Lymphoma
  • Non-hodgkins Lymphoma
Not Provided
Malignant Disease with no visualized BAT
Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients had PET/CT scans with evidence of malignant disease
  • Patients had no metabolically active BAT at diagnosis on their PET/CT scan
  • Patients were disease free within 1 year of diagnosis

Exclusion Criteria:

  • Patients had PET/CT scans with no evidence of malignant disease
  • Patients with metabolically active BAT at diagnosis on their PET/CT scan
  • Patients were not disease free within 1 year of diagnosis
Both
6 Years to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01517581
CHLA-Gilsanz-BAT/WAT
No
Vicente Gilsanz, Children's Hospital Los Angeles
Children's Hospital Los Angeles
Not Provided
Principal Investigator: Vicente Gilsanz, MD, PhD Children's Hospital Los Angeles
Children's Hospital Los Angeles
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP